Authors : Karicharla SreeYamini Kalpana; Peram Divya; Sanagam Shambhavi; Dandra Niveditha; Dr. Srinivas Chinta

Volume/Issue : Volume 11 - 2026, Issue 2 - February

Google Scholar : https://tinyurl.com/n9c7a5mk

Scribd : https://tinyurl.com/mrx2ydsr

DOI : https://doi.org/10.38124/ijisrt/26feb1142

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Background: Because of the complimentary ways in which Metformin and Canagliflozin work together, fixed-dose combination pills are frequently used to treat type 2 diabetes mellitus. For routine quality control of such formulations, a rapid, reliable, and sensitive analytical method is required.  Aim and Objective: In compliance with ICH recommendations, the current work sought to create and validate a straightforward, accurate, precise, and robust Ultra Performance Liquid Chromatography (UPLC) method for the simultaneous estimation of metformin and canagliflozin in tablet dose form.  Methods: Using a mobile phase of phosphate buffer (pH 3.0) and acetonitrile (60:40, v/v) at a flow rate of 0.3 mL/min, chromatographic separation was accomplished on a C18 column. UV detection was carried out at 230 nm for metformin and 264 nm for cnagliflozin. The method was validated for specificity, linearity, accuracy, precision, limit of detection (LOD), limit of quantification (LOQ), and robustness.  Results and Discussion: Metformin and Canagliflozin were well separated with retention times of approximately 2.10 min and 3.53 min, respectively, and a resolution greater than 3.0. The method showed excellent linearity in the concentration ranges of 10– 100 µg/mL for Metformin and 1–20 µg/mL for Canagliflozin with correlation coefficients (r²) of 0.999 and 0.999, respectively. Precision studies showed %RSD values below 1%, indicating good repeatability. Accuracy studies yielded recoveries in the range of 99.0–100.8% for Metformin and 99.0–100.6% for Canagliflozin. The LOD and LOQ were found to be 0.12 and 0.36 µg/mL for Metformin and 0.2 and 0.73 µg/mL for Canagliflozin, respectively, demonstrating good sensitivity. Assay of the marketed tablet formulation showed drug content of 99.7% for Metformin and 101.2% for Canagliflozin.  Conclusion and Outcome: The developed UPLC method is simple, rapid, accurate, precise, and sensitive, and is suitable for routine quality control analysis of Metformin and Canagliflozin in combined tablet dosage forms.

Keywords : UP-LC, Metformin, Canagliflozin, Simultaneous Estimation, Validation, Tablet Dosage form.

References :

1. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2022;45(Suppl 1):S1–S264.
2. Abdul-Ghani MA, Norton L, DeFronzo RA. Role of sodium–glucose cotransporter 2 (SGLT2) inhibitors in the treatment of type 2 diabetes. Endocr Rev. 2011;32(4):515–531.
3. DeFronzo RA, et al. Combination of Metformin and SGLT2 inhibitors in the management of type 2 diabetes. Diabetes Obes Metab. 2017;19(10):1353–1362.
4. Neal B, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377:644–657.
5. Indian Pharmacopoeia Commission. Indian Pharmacopoeia. Ghaziabad: IPC; Latest Edition.
6. Patel D, Shah U, Patel J, et al. A stability indicating RP-HPLC method validation for simultaneous estimation of Metformin HCl and Canagliflozin in pharmaceutical dosage form. J Pharm Res Int. 2021;33(56A):180–192.
7. Zaghary WA, Mowaka S, Hendy MS. Comparative liquid chromatographic study for concurrent determination of Canagliflozin and Metformin in combined tablets. J Anal Methods Chem. 2017; Article ID 9197230.
8. Lekurwale S, Shaikh S, Khairnar S, et al. RP-HPLC method development and validation for simultaneous estimation of Canagliflozin and Metformin in bulk and dosage form. World J Pharm Life Sci. 2021;7(11):144–150.
9. Swartz ME. UPLC: An introduction and review. J Liq Chromatogr Relat Technol. 2005;28(7–8):1253–1263.
10. Mohamed D, Elshahed MS, Nasr T, et al. Novel LC-MS/MS method for analysis of Metformin and Canagliflozin in human plasma: application to a pharmacokinetic study. BMC Chem. 2019;13:82.
11. ICH Q2(R1). Validation of Analytical Procedures: Text and Methodology. International Conference on Harmonisation; 2005.